Gadoxetic Acid
A gadolinium-based contrast agent used in magnetic resonance imaging of the liver, taken up selectively by functional liver cells to provide detailed images of liver structure and detect lesions such as tumors or cirrhosis. It combines the benefits of standard extracellular MRI contrast with liver-specific enhancement during the hepatobiliary phase. It helps physicians distinguish between benign and malignant liver conditions.
Molekularmasse
681,7000 g/mol
TPSA
220,00 Ų
Therapeutische Bereiche
Wirkmechanismus
Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.
2D-Struktur
Cite this structure
Embed this structure
SMILES
[H+].[H+].CCOC1=CC=C(C=C1)C[C@@H](CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])N(CC(=O)[O-])CC(=O)[O-].[Gd+3]
InChI
InChI=1S/C23H33N3O11.Gd/c1-2-37-18-5-3-16(4-6-18)9-17(26(14-22(33)34)15-23(35)36)10-24(11-19(27)28)7-8-25(12-20(29)30)13-21(31)32;/h3-6,17H,2,7-15H2,1H3,(H,27,28)(H,29,30)(H,31,32)(H,33,34)(H,35,36);/q;+3/p-3/t17-;/m0./s1
Molecular Formula
C23H30GdN3O11
HBD / HBA
2 / 14
Rotierbare Bindungen
15
Schwere Atome
38
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
A gadolinium-based contrast agent used in magnetic resonance imaging of the liver, taken up selectively by functional liver cells to provide detailed images of liver structure and detect lesions such as tumors or cirrhosis. It combines the benefits of standard extracellular MRI contrast with liver-specific enhancement during the hepatobiliary phase. It helps physicians distinguish between benign and malignant liver conditions.
Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.
Yes, Gadoxetic Acid is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2221312. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 25203894. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="gadoxetic-acid"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/gadoxetic-acid/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/gadoxetic-acid/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/gadoxetic-acid/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="gadoxetic-acid"></drugfyi-drug>